TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Implant: The implant additionally comprises at least one coating that alter the rate of the first active agent elution from the implant, where at least the distal-most 5-10 mm of the interior lumen houses the drug. The elution of the first active drug from the implant continues for at least a period of at least one year. The implant further comprises a lumen configured to transport ocular fluid from a first location in an eye to other locations, thereby reducing intraocular pressure. The implant further comprises a shunt configured to transport ocular fluid from the anterior chamber to physiological outflow pathways, thereby reducing intraocular pressure. Preferred Method: In the method (M1), inserting the drug delivery ocular implant into eye tissue involves placing at least a portion of the implant in a portion of the eye selected from uveoscleral outflow pathway, suprachoroidal space, and Schlemm's canal. In the method (M2), piercing of the sclera is performed using an apparatus have a sharpened proximal end, where the hole within the sclera is sufficiently small to be self-healing.    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: The micro-tablets have a minor axis of 0.28-0.31 mm and a major axis of 0.8-1.1 mm. The elongate shell is formed by extrusion. The elongate shell comprises a biodegradable polymer. The first active drug is present in an amount of at least 70 wt.% of a total weight of the micro-tablets. The micro-tablets have a surface area to volume ratio of 13-17. The micro-tablets have dimensions allowing passage of the micro-tablets through a conduit having an inner diameter of 23-25 gauge. The micro-tablets are formed by utilizing at least one process selected from tabletting, lyophilization, granulation (wet or dry), flaking, direct compression, molding, and extrusion. The micro-tablets are configured to balance osmotic pressure between the interior lumen and the ocular environment external to an implant after implantation. The micro-tablets are coated with a coating that regulates the release of the first active drug from the micro-tablet, where the coating is a polymeric coating. The outer shell is permeable or semi-permeable to the first active drug, thereby allowing at least 5% of total the elution of the first active drug to occur through the portions of the shell having the first thickness. The first active drug is an anti-angiogenesis agent. The first active drug is selected from angiostatin, anecortave acetate, thrombospondin, VEGF receptor tyrosine kinase inhibitors and anti-vascular endothelial growth factor (anti-VEGF) drugs. The anti-VEGF drugs are selected from ranibizumab, bevacizumab, pegaptanib, sunitinib and sorafenib, preferably bevacizumab. The regions of drug release are configured to allow a different rate of drug elution as compared to the elution through the outer shell. The overall rate of elution of the first active drug out of the implant is greater in the distal region of the implant, where there is a greater amount of the first active drug in the distal half of the implant as compared to the proximal half of the implant. The regions of drug release comprise regions of reduced thickness shell material and/or orifices passing through the outer shell. The regions of drug release comprise orifices and where the orifices are positioned along the long axis of the implant shell. The intraocular target is in the posterior chamber of the eye. The intraocular target is selected from macula, retina, optic nerve, ciliary body, and intraocular vasculature. The first active drug elutes from the implant so as to achieve a therapeutic effect for a period of at least one year. The micro-tablet has a minor axis of 0.28-0.31 mm and a major axis of 0.8-1.1 mm, where each of the micro-tablets has an aspect ratio of length to diameter of 2.8-3.6.    TECHNOLOGY FOCUS - POLYMERS - Preferred Components: The outer shell comprises polyurethane. The polyurethane comprises a polysiloxane-containing polyurethane elastomer. ACTIVITY - Ophthalmological. No biological data given.    MECHANISM OF ACTION - None given.    EXAMPLE - No suitable example given.